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Abstract
Various molecular pharmacokinetic–pharmacodynamic (PK–PD) models have
been proposed in the last decades to represent and predict drug effects in anti-
cancer chemotherapies. Most of these models are cell population based since
clearly measurable effects of drugs can be seen, much more easily than in individ-
ual cells, on populations of cells, healthy and tumour.
The actual targets of drugs are, however, cells themselves. The drugs in use
either disrupt genome integrity by causing DNA strand breaks, and consequently
initiate programmed cell death, or block cell proliferation mainly by inhibiting
factors that enable cells to proceed from one cell cycle phase to the next through
checkpoints in the cell division cycle. DNA damage caused by cytotoxic drugs
(and also cytostatic drugs at high concentrations) activates, among others, the p53
protein-modulated signalling pathways that directly or indirectly force the cell to
make a decision between survival and death.
The paper aims to become the first-step in a larger scale enterprise that should
bridge the gap between intracellular and population PK–PD models, providing on-
cologists with a rationale to predict and optimise the effects of anticancer drugs in
the clinic. So far, it only sticks at describing p53 activation and regulation in single
cells following their exposure to DNA damaging stress agents. We show that p53
oscillations that have been observed in individual cells can be reconstructed and
predicted by compartmentalising cellular events occurring after DNA damage, ei-
ther in the nucleus or in the cytoplasm, and by describing network interactions,
using ordinary differential equations (ODEs), between the ATM, p53, Mdm2 and
Wip1 proteins, in each compartment, nucleus or cytoplasm, and between the two
compartments.
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1. Introduction
Shortly after disruption of the integrity of the genome of a cell by various
pharmacological agents or ionising radiations, the cell responds dynamically by
activating a variety of recognition and repair proteins recruited to DNA damage
sites, by initiating various signalling pathways leading either to cell cycle arrest
and parallel DNA repair, or permanent cell cycle arrest, or else cell death. Among
these pathways, one of the most important ones is the network of the tumour sup-
pressor protein p53, the so-called guardian of the genome, that initiates expres-
sion of those genes that ultimately govern cell cycle arrest, DNA damage repair
and apoptosis, involving the production of proteins of concentrations proportion-
ally related to the concentrations of p53 [1]. At the cell population level (i.e.,
tissues, organs, whole human body) pharmacokinetics–pharmacodynamics (PK–
PD) modelling has been broadly used to fully describe absorption, distribution,
metabolism, excretion and toxicity of anticancer drugs. Much less, however, has
been done at the single cell (molecular) level to describe drug effects, considering
that individual cells are the actual targets of drug administration [2]. Some drugs
(e.g., the cytotoxic drug, alkylating agent, oxaliplatin) directly cause DNA double
strand breaks (DSBs), others target essential cell cycle enzymes (such as topoi-
somerases or thymidylate synthase), leading to the production of abnormal DNA
and forcing the cell to start the process of apoptosis, at least when DNA cannot be
repaired [3].
Thus, to reproduce more realistically drug effects in cancer treatments, as de-
scribed by PK–PD models with DNA damage as output, it may be helpful to
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include in existing models processes that appear in individual cells after DNA in-
sult, beginning with a proper understanding of p53 activation and activity in single
cells, with the perspective of subsequent integration of such activity into a cell fate
decision process. Bearing in mind that p53 is inactive due to its gene mutations
in around 50% of tumour cells, with the rate varying from 10–12% in leukaemia,
38–70% in lung cancers to 43–60% in colon cancers, etc. [4], approaches in-
volving processes occurring in individual cells with the dominant role of p53 can
contribute to establishing new cancer therapies that could either restore p53 lost
functionality or substitute for it in the activation of subsequent proteins in various
p53-initiated pathways.
In this modelling enterprise, the main object of interest at the single cell level
is thus the protein p53, its activation and its activity on proarrest and proapoptotic
genes that enable the cell to make a decision between cell cycle arrest and DNA re-
pair, permanent arrest of cell growth (so-called senescence) and cell death (apop-
tosis). Note that the first p53-transcription independent wave of cells committing
apoptosis in response to γ-irradiation is observed 30 min after DNA damage by
rapid accumulation of p53 in the mitochondria. The second wave comes after a
longer time phase and a decision of the cell to undergo apoptosis in this wave is
determined by the concentrations of both proapoptotic and proarrest proteins, the
expression of which is modulated by p53 [1, 4]. However, different sorts of such
apoptotic proteins are produced, in a cell–stress, cell–type and tissue–type depen-
dent manner. Various post-translational modifications, interactions of p53 with
over 100 cellular cofactors and p53 cellular location have effects on determining
what kind of proteins and when these proteins are produced [4].
The regulation of p53 is mainly achieved through its interactions with the
Mdm2 ligase, that itself is a transcription target for p53. Mdm2 regulates p53
through (multiple-)ubiquitination process, followed by nuclear export and sub-
sequent degradation of tagged p53 molecules. Phosphorylation of p53 serine 15
(Ser15) residue, which is located very close to the p53 kinase domain — the target
of Mdm2 — can mask it from Mdm2 ubiquitination and hence stabilise it at its
highest concentrations [5, 6, 7]. In response to DSBs, p53 can be phosphorylated
on Ser15 in three independent ways, among which is phosphorylation by the ATM
kinase [7]. Phosphatase Wip1 is another p53 target which acts in the pathway as
a regulator; particularly, it dephosphorylates both ATM and p53, rendering them
inactive, whence Wip1 closes negative feedback loops between these proteins as
is schematically shown on Figure 1.1.
In this article we model and simulate in silico ATM/p53/Mdm2/Wip1 dynam-
ics of protein interactions in the p53 signalling pathway in response to DNA DSBs
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Figure 1.1: The ATM/p53/Mdm2/Wip1 dynamics.
at the single cell level, aiming at further representing cell fate decision in future
cell population models. This model is indeed intended to become a first step
in narrowing the gap between intracellular and cell population PK–PD models.
Compartmental and spatial p53/Mdm2 models developed by Dimitrio et al. [5, 6]
are here extended by considering the ATM and Wip1 proteins. In these mod-
els ATM is interpreted as an identifier of DNA DSBs, although it is not a direct
DNA DSB sensor [8]. However, unlike in the originally proposed model, and with
the perspective to involve p53 in further PK–PD models, we integrate ATM and
Wip1 into the p53/Mdm2 dynamics so that p53 activation and regulation can be
modelled more plausibly with respect to relevant biological observations. In the
original model, compartmentalisation of cellular events together with p53/Mdm2
feedback (p53 → Mdm2 a 53) led to the desired p53 oscillatory behaviour even
with constant ATM parameter (considered as a measure of DNA damage). Under
our new assumptions, ATM concentration is considered as a continuous time-
dependent function, and we show that the feedbacks p53 → Mdm2 a p53 and
AT M → p53 → Wip1 a AT M together with compartmental distribution of pro-
teins can then reconstruct the oscillatory dynamics of these proteins.
The paper is organised as follows: In Section 2, we give a short biological
background of our subject in relation with physiologically based PK–PD mod-
elling. Then in Section 3, we present motivations for our modelling work, by
firstly describing in detail known mechanisms of p53 activation, p53 activity to-
wards its substrates and links between DNA damage and ATM activation. Then
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specifications for the proposed model and its computer simulation are presented
in Section 4; this section contains our results with their physiological interpreta-
tions. Mathematical details, including the complete systems of equations with the
parameters chosen for simulations, and some illustrative plots, are presented in
the Appendices A to D.
2. Cancer therapies and PK–PD models
Most cytotoxic and cytostatic drugs used in cancer treatments act in a selective
manner, taking advantage of differences in tumour cell characteristics, compared
to healthy cells, such as high proliferation rates, genome instability and tolerance
to hypoxia. This results in proper targeting of chemotherapeutic agents on tu-
mour cells. However, cancer therapies also have toxic side effects on healthy cells
and can lead to the disruption of physiological functionality of tissues and or-
gans. In the particular case of chronotherapeutic settings (i.e., hypothesizing best
treatment periods in the 24 hour span), physiologically based molecular PK–PD
models using ODEs have been proposed for the cytotoxic drugs Oxaliplatin [3],
5-Fluorouracil [3, 9] and Irinotecan [10, 11], all three drugs that are commonly
used in the treatment of metastatic colorectal cancer. Moreover, to minimise such
unwanted effects in more general (non chrotherapeutic) settings, most anticancer
drugs are delivered in the clinic in time interval-depending regimens to allow
cells to recover their normal functions after pharmacological insult. However,
time intervals between chemotherapy courses also allow tumour cells to recover,
activating their survival mechanisms, and further resist subsequent therapeutic in-
sults. Optimal scheduling strategies are currently being theoretically investigated
[2, 3, 12] to obtain satisfying trade-offs between the objective of reducing the tu-
mour burden without inducing neither intolerable side effects on healthy cells nor
emergence of resistant clones in the tumour cell population.
Besides toxic side effects on healthy cells, tumour cells can indeed often de-
velop multiple resistance to drugs. Moreover, in vivo observations in the tumour
stromal tissue surrounding tumours of prostate, breast and ovary reveal the drug-
induced production of a spectrum of secreted cytokines and growth factors, e.g.,
WNT16B, that promote tumour growth and survival of cancer cells after cytotoxic
therapy, and further reduce chemotherapy sensitivity in tumour cells, resulting in
tumour progression; otherwise said, among other constraints, one must take into
account the fact that chemotherapy itself can positively influence the growth of
tumours [13].
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In order to take into account these different therapy-limiting constraints, opti-
mal administration of anticancer agents should involve accurately representing the
action of drugs at the molecular, i.e., intracellular, level, which means molecular
pharmacokinetic-pharmacodynamic (PK–PD) modelling for each drug used in a
given treatment firstly at the level of a single cell and secondly (not described in
this work) at the level of cell populations, i.e., tissues and organs. The review we
present here of p53 molecular mechanisms of action, and their modelling, is po-
sitioned in continuity with, but downstream of, the action of cytotoxic anticancer
drugs, when DNA damage is constituted, so that DNA damage is the interface
between molecular PK–PD models (not recalled here) and the model we propose
in Section 4, based on physiological mechanisms reviewed in Section 3.
3. p53 signalling in DNA damage response
Currently, one can find in the scientific literature a large number of papers
contributing to describing p53 signalling in detail. In the following sections we
point out only the most important facts that are further recalled and used in the
model development. Detailed overviews of the p53 transcriptional activity can be
found in the works of Murray-Zmijewski et al. [4] and Vogelstein et al. [7].
3.1. p53 activation and regulation
The tumour suppressor protein p53 can be activated in at least three indepen-
dent ways: DNA damage caused, for example, by ionising radiation or electro-
magnetic γ radiation, with initial activation of ATM and Chk2 proteins; aberrant
growth signals; and various chemotherapeutic drugs, UV radiation and protein–
kinase inhibitors. All three ways inhibit p53 degradation and enable the protein to
accomplish its main transcriptional function [7].
The concentration of p53 in cells is determined mainly through its degradation.
To prevent p53 degradation following DNA damage, ATM (or Chk1, Chk2 and
DNA-dependent protein kinases) phosphorylates p53 on Ser15 localised at the
amino-terminal sites (in vitro and in vivo) very close to the binding site of its main
regulator Mdm2. Phosphorylation of Ser15 masks p53 from Mdm2 (it blocks
binding Mdm2 to p53); it stabilises p53 at high concentrations and thus it initiates
p53 transcriptional activity [5, 6, 7].
Phosphatase Wip1, a transcription target of p53, is then observed to act in the
reverse way, compared with the action of ATM. It dephosphorylates both ATM
and p53, making them inactive and unable to phosphorylate their substrates; in
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particular, inactive ATM cannot phosphorylate p53 on Ser15 and dephosphory-
lated p53 is then detectable by Mdm2, as represented on Figure 1.1 [14, 15, 16].
The E3 ligase Mdm2 is another transcription target of p53. Its p53-inhibiting
activity consists in multiple ubiquitination. More precisely, Mdm2 binds the
amino-terminus of p53 after Ser15 dephosphorylation and recruits E2 ligases,
which directly attach ubiquitines (small peptides) to Lys residues at the carboxyl-
terminus of p53. The ubiquitinated p53 protein is then exported to the cytoplasm
where it is easily detected by the protein-degrading machinery [7]. Other proteins
such as HAUSP can contribute to p53 stability by deubiquitination of p53, i.e. by
opposing Mdm2 [4].
Among other things, full p53 transcriptional activation and stabilisation in
highly specific situations require other post-translational modifications (phospho-
rylation, acetylation, methylation, sumoylation, ubiquitination, etc.) of one or
more p53 residues. The particular p53 activity is even more complicated consid-
ering that different modifications of the same p53 residue, e.g. methylation and
ubiquitination of Lys370, result in different p53 effects [4].
3.2. p53 transcriptional activity towards proarrest and proapoptotic proteins
The protein p53 as a transcription factor can activate hundreds of genes in re-
sponse to a variety of stress signals, thus transforming such signals into various
cellular responses. In addition, the p53 transcriptional activity is heterogeneous,
depending not only on the incoming signal (its type and amplitude) but also on
many other factors — the environment of the cell, type of cells, tissues, presence
and abundance of cellular cofactors and enzymes causing modifications of over
thirty residues of p53, etc.. All this can induce alterations in p53 stability, expres-
sion of substrate genes and cellular location [4].
Experiments on p53 activity on its substrates initially suggested that p53 ac-
tivates genes likely with respect to its affinity for a specific promoter. Such con-
ception, for example, assumed that low concentrations of p53 predominantly lead
to the activation of genes of high binding affinity, mostly the genes coding for
proarrest proteins. When the concentration of p53 is high, then it activates also
genes of low binding affinity (i.e. proapoptotic genes). However, this view has
been partially disproved by observations evidencing that post-translational modi-
fications contribute to both proarrest and proapoptotic proteins activation without
any preference being due to p53 affinity towards promoters [4]. Recent experi-
ments by Kracikova et al. [1] support these ideas and contradict models based on
a differential p53 affinity by showing that even low levels of p53 can activate both
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proarrest and proapoptotic genes, and that concentrations and durations of the ex-
pression of p53 substrates are determined only by concentration and duration of
expression of p53 itself.
Importantly, a stressed cell evaluates the presence of both proarrest and pro-
apoptotic proteins produced in a p53-dependent manner at any time during its
response to DNA damage. The cell determines a so-called “apoptotic ratio” with
respect to protein concentrations, duration of their expression and other factors.
Irreversible apoptosis launching is initiated whenever this ratio crosses a given
threshold [1]. Expression of those apoptosis-launching proteins is a rather com-
plex process that depends on many factors (post-translational modifications, in-
teractions with other cellular substrates, location, etc.), but from an intracellu-
lar PK–PD modelling point of view, the most interesting part, i.e. apoptotic
response to therapeutic drugs, must certainly involve p53. However, modelling
p53-modulated further cell fate decision (apoptosis or repair and survival, with
possible senescence) is omitted from this paper and left for further research, sim-
ply because of so far insufficient biological knowledge of the intracellular (and
intercellular) mechanisms at stake. In this paper, we review, model and simulate
the activation and regulation of p53 through the ATM, Wip1 and Mdm2 proteins.
3.3. p53 oscillations in single cells; dependency of such oscillations on ATM
Experiments in individual living breast cancer cells show that concentrations
of p53 and Mdm2 exhibit sustained oscillations [17] of duration over several days,
with slightly varying period and widely varying amplitude from peak to peak, also
with a number of pulses different from cell to cell, following γ-irradiation [18].
Originally observed damped oscillations that have been measured in immunoblots
[19] are likely caused by cancelling of pulses in a population of cells. Note also
that not all cells exhibit oscillations in proteins after DNA damage; however, the
fraction of oscillating cells increases with the irradiation dose [18].
Further single-cell experiments on the p53/Mdm2 dynamics reveal that the
p53/Mdm2 feedback loop itself is not sufficient to produce sustained oscillations
[14]. Instead, the p53 pulses depend on oscillations of the proteins that sense and
transmit the damage signal to p53, particularly ATM and Chk2 (Chk2 itself is a
target for ATM), and on the second negative feedback loop between p53 and the
phosphatase Wip1, which is schematically illustrated on Figure 1.1. Even thus,
the initial activation of p53 by ATM and Chk2 is not sufficient to generate mul-
tiple p53 pulses, and sustained p53 pulses are detectable in parallel to sustained
ATM and Chk2 oscillations only; whenever ATM activity is inhibited, oscillatory
behaviour of p53 also vanishes [14].
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Hence, although Mdm2 is important for the regulation of p53, Mdm2 without
ATM and Wip1 does not lead to p53 oscillations. We thus propose that a model
capturing initiation and regulation of p53 activity must involve the ATM and Wip1
proteins, the dynamics of which should be fully described by mathematical vari-
ables, solutions of ODEs, rather than represented by constant parameters.
3.4. Compartmentalisation
The p53 protein is a predominantly nuclear protein, which is understandable
since its main role consists in the transcriptional activation of many other pro-
teins. However, p53 can also play a part outside of the nucleus, notably as a
transcription-independent factor involved in apoptosis induction [4, 20]. Note
that there are many cellular substrates affecting p53 location. For example, the E3
ligase E4F1 contributes to stronger association of p53 with chromatin through
multiple ubiquitination, and the PARP1 polymerase positively affects nuclear
accumulation and inhibits nuclear export. On the other hand, Mdm2–mono–
ubiquitination of p53 can promote p53 sumoylation with the consequences of
effective p53 nuclear export [4].
ATM is also predominantly concentrated in the nucleus with only 10-20%
of its molecules found in the cytoplasm, particularly bound to peroxysomes and
endosomes [21]. Fluorescent microscopy techniques have confirmed this spatial
distribution of ATM between the nucleus and the cytoplasm. However, only the
nuclear fraction of ATM is autophosphorylated in response to DNA damage in-
duced by ionising radiation, and activated ATM proteins form detectable foci that
are colocalised with foci of γH2AX, a marker of DNA DSBs. Cytoplasmic ATM
can neither autophosphorylate itself nor phosphorylate its substrates [22].
The p53-mediated expression of Mdm2 and Wip1 genes produces in the cy-
toplasm proteins that can freely migrate between the nucleus and the cytoplasm.
However, the protein Wip1 is mostly observed to accumulate in the nucleus fol-
lowing ionising radiation [23].
3.5. ATM activity on p53
Although p53 activation by ATM in response to DNA damage is well docu-
mented, the precise mechanisms of this activation are less well known. We present
in Section 3.5.3 an overview of recent biological observations related to the ATM
activation and activity. A schematic representation of the ATM protein is shown
on Figure 3.1.
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Figure 3.1: Schematic representation of ATM. ATM is a 370 kDa protein with a
350-amino-acid kinase domain between an internal FAT domain, and a carboxyl-
terminus FATC domain. ATM substrates such as p53 and Nbs1 bind to a region
near the N-terminus (amino acids 1–989) of the protein substrate binding site
(SBS). Deletion of SBS inactivates the protein [21]. The nuclear importins α1 and
β1 are identified very close to the N-terminus. The N-terminus of ATM is crucial
for both nuclear location and chromatin association, optimal ATM activation and
subsequent ATM activity in vivo [22]. Wip1 binds to the N-terminus and FAT
domain, which contain Ser367 and Ser1981, respectively [16].
3.5.1. ATM activation
In unstressed human cells ATM exists in inactive form as a compound formed
(dominantly) from two ATM molecules, which makes it stable in cells, retaining
it in a constant concentration, and inaccessible to cellular substrates [24, 25]. In
this polymer form, the kinase domain of ATM is bound to a region surrounding
Ser1981 that is contained within the FAT domain of ATM, as shown on Figure 3.2.
A cell exposure to stress agents (ionising radiation or cytotoxic drugs) induces
rapid autophosphorylation of ATM onSer1981 and this phosphorylation results
in dimer dissociation and initiation of cellular ATM kinase activity in vivo. In
ATM dissociation and activation, the active site of one ATM kinase (one out of
two bound in the dimer) catalyses the phosphorylation reaction within which a
phosphate group, commonly coming from ATP, is added to Ser1981 of the an-
other ATM kinase (resulting in the so called trans-autophosphorylation), shown
on Figure 3.2 [24].
Occasional double strand breaks (DSBs) arising, for instance, from DNA
replication are normally promptly corrected by the DNA repair machinery, with
either no need to activate ATM or such activation being only moderate and tem-
porary [26]. After DNA damage caused by other agents (at even as low doses
as 0.1 Gy of ionising radiation), ATM activation occurs very promptly [24, 27].
ATM forms clearly detectable foci adjacent to DNA DSBs, and even relatively low
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Figure 3.2: ATM forming a dimer in an unstressed cell (above) and dimerisation
of the dimer into active monomers through autophosphorylation of Ser1981 after
DNA damage.
levels of nuclear ATM may be sufficient to elicit proper responses to DNA dam-
age [22]. In addition to exposure of cells to ionising radiation, cytotoxic drugs and
restriction enzymes causing DNA DSBs, phosphorylation of Ser1981 and ATM
activation is also detectable by introducing chromatin-modifying treatments such
as chloroquine or histone deacetylase inhibitors, which do not induce DSBs [24].
3.5.2. ATM activity
In vivo, ATM activation following ionising radiation occurs very rapidly at
distance from DNA DSBs, by means of Ser1981 autophosphorylation. Impor-
tantly, the kinetics of p53 phosphorylation on Ser15, and thus p53 activation, cor-
responds to the kinetics of ATM activation. Indeed, phosphorylation of p53 is
similarly maximal at doses of 1–3 Gy of ionising radiation with little or no further
increase up to doses of 30 Gy in fifteen minutes. Clearly detectable p53 phospho-
rylation also occurs after employing chromatin-modifying treatments not causing
DSBs [24, 27].
In contrast, phosphorylation of the ATM substrates SMC1 (on Ser957), Nbs1
(on Ser343) and H2AX (on Ser139) occurs at the sites of DNA DSBs and in-
creases continuously in a dose-dependent manner up to 30 Gy. Furthermore,
foci of these proteins are not detectable in case of chromatin modifying treat-
ments [24, 27]. In these cases ATM associates with DNA break sites and the
ATM attraction to unwinding DNA break ends is modulated by the C-terminus of
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Nbs1 [28], a part of the complex of Mre11/Rad50/Nbs1 proteins that actually acts
as a sensor of DNA DSBs [8].
Similarly to additional post-translational modifications of p53, ATM contains
residues undergoing various modifications, e.g. phosphorylation of the ATM sites
Ser367, Ser1893, Ser2996 and Thr1885, that influence various ATM roles in the
ATM signalling pathway, mainly at the intra-S phase checkpoint [29, 30]. Acety-
lation of Lys3016 by Tip60 has been observed in parallel to Ser1981 phospho-
rylation as a crucial event in ATM kinase activation and monomerisation [31].
Inactive or phosphorylation site mutants of ATM fail to bind to DNA DSBs in
vivo [32].
3.5.3. ATM regulation
Unlike for p53, the stability of ATM is not determined through its degradation,
but rather by reverse association of monomers to dimers (or multimers), i.e. de-
phosphorylation of active ATM monomers by some phosphatases and backward
dimerisation (multimerisation) of such dephosphorylated monomers.
Abundance and activity of several phosphatases can affect ATM monomerisa-
tion and dimerisation, such as phosphatases PP5 [33] and PP2A [34] of the PPP
phosphatase family, among which PP2A is likely the only member of this family
which can dephosphorylate ATM [34].
Phosphatase Wip1 is also known to dephosphorylate ATM Ser1981 [15]. It has
been shown that inefficient Wip1 results in ATM kinase malfunction, and overex-
pression of Wip1 significantly reduces protein activation in the ATM-dependent
signalling cascade after DNA damage. The ATM Ser1981 site is the main tar-
get of Wip1 in vivo and in vitro. Moreover, it can dephosphorylate other ATM
sites [16]. The protein Wip1 has many other targets in p53 signalling pathway —
it dephosphorylates, for example, p53, Chk1 and HA2X.
4. ATM/p53/Mdm2/Wip1 compartmental model
In this section, we design and analyse a mathematical model that can suc-
cessfully be used to reconstruct in silico experimentally observed dynamics of
proteins, namely, the main cellular actor p53, ATM as a protein transferring the
DNA damage signal, Wip1 as a dephosphorylation factor of both p53 and ATM,
and Mdm2, that tags p53 for degradation. Note that our model is compartmental
in the sense that we strictly distinguish the activities of proteins occurring in the
nucleus from those occurring in the cytoplasm, as it is shown on Figure 4.1. Note
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also that the model proposed in this section is an extension of the compartmental
model developed by Dimitrio et al. [5, 6].
4.1. Model specifications
4.1.1. Modelling ATM activation and deactivation
ATM activation, i.e., its autophosphorylation and consequent dissociation of
ATM dimers into (active) monomers, can be modelled in several ways. The sim-
plest way is through the dissociation reaction
AT MD
km

k−m
AT Mp + AT Mp, (1)
where AT MD denotes a compound of two ATM kinases and AT Mp is active (phos-
phorylated) ATM. In our model, ATM in inactivate state is considered in form of
dimers only. The constants km and k−m denote, respectively, the monomerisation
(forward) and dimerisation (reverse) rate constants of reaction. Reaction (1) in-
volves monomerisation (dissociation) of a dimer complex AT MD to the two active
ATM species with the rate km and dimerisation of two AT Mp monomers to pro-
duce AT MD with the rate k−m. The law of mass action then gives mathematical
relations between AT MD and AT Mp (not shown), with the production of AT MD
being equal to the half production of AT Mp [35]. A disadvantage of presenting
the activation/deactivation of ATM as in (1), however, is that it does not mention
any signal initiating AT MD dissociation, whereas such a signal is thought to be
produced by changes in chromatin structures after DNA damage [24] and/or by
the MRN complex as a DNA strand breaks sensor [8].
Hence, a more convenient way to represent ATM activation with the perspec-
tive of further analysis is to involve a hypothetical, likely molecular and so far
unidentified DNA damage signal, that will be denoted by E, produced by DNA
damage recognition sensors, transmitted to and sensed by ATM, resulting in the
dissociation of ATM dimers into two molecules of AT Mp, i.e.,
AT MD + E
ki

k−i
Complex
kph2−→ E + 2 AT Mp (2)
with the corresponding kinetic rates ki, k−i and kph2. This reaction is not a typi-
cal enzymatic reaction since the enzyme-like signal E is in this approach a non-
specified signal corresponding to DNA damage; it is not necessarily an enzyme;
however, we assume that E is not amplified, reduced nor otherwise changed in a
short time interval.
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ATM deactivation by Wip1 is modelled similarly as
Wip1 + 2 AT Mp
k j


k− j
Complex
kdph2−→ AT MD + Wip1. (3)
Here, it is assumed that phosphatase Wip1 exists in sufficient concentration to
dephosphorylate ATM active monomers in the sense that whenever one AT Mp
protein is dephosphorylated, another dephosphorylated ATM protein is present, so
that they are immediately bound to the dimeric AT MD. Kinetic rates are denoted
by k j, k− j and kdph2.
Note that ATM activation and deactivation by Wip1 occur in the nucleus.
The law of mass action and the quasi-steady-state approximation [35, 36] then
yield differential equations, hereafter (2) and (3); in particular, changes of concen-
trations in time of AT MD and AT Mp are, respectively,
d[AT MD]
dt
= −kph2[E] [AT MD]Kph2 + [AT MD] + kdph2[Wip1]
[AT Mp]2
Kdph2 + [AT Mp]2
,
d[AT Mp]
dt
= 2kph2[E]
[AT MD]
Kph2 + [AT MD]
− 2kdph2[Wip1] [AT Mp]
2
Kdph2 + [AT Mp]2
,
(4)
since the production of AT MD is half that of AT Mp. Here Kph2 =
k−i+kph2
ki
and
Kdph2 =
k− j+kdph2
k j
are the Michaelis-Menten rates of reactions (2) and (3), while
kph2 and kdph2 are the velocities of these reactions, [·] denotes concentration.
ATM has not been observed to be degraded during its signalling activity but,
after dephosphorylation by Wip1, it rather forms a compound with another ATM
dephosphorylated kinase, thus preserving ATM in a stable concentration [24, 32].
Hence, we require ATM to satisfy a conservation property expressing the fact that
the total concentration of nuclear ATM kinases (monomers and kinases bound in
dimers) is constant during the considered time period, i.e.,
[AT Mp] + 2[AT MD] = AT MTOT ,
where AT MTOT is the constant total ATM concentration. Using this conservation
property, equations in (4) can actually be merged into one equation.
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4.1.2. Modelling p53/Mdm2 negative feedback
The dynamics of p53/Mdm2/Wip1 in the nucleus can be expressed by the
following reactions:
p53 + Mdm2
k

k−
Complex
k1−→ p53U + Mdm2
. . . for p53 ubiquitination by Mdm2,
AT Mp + p53
k2

k−2
Complex
k3−→ p53p + AT Mp
. . . for p53 phosphorylation by ATM,
Wip1 + p53p
k4

k−4
Complex
kdph1−→ p53 + Wip1
. . . for p53 dephosphorylation by Wip1,
(5)
with the corresponding kinetic constants.
Again, the application of the law of mass action and the quasi-steady-state
approximation yields the equations for time changes of the nuclear inactive p53
and active p53p concentrations, i.e.,
d[p53]
dt
= kdph1[Wip1]
[p53p]
Kdph1 + [p53p]︸                             ︷︷                             ︸
dephosphorylation of p53p by Wip1
− k1[Mdm2] [p53]K1 + [p53]︸                      ︷︷                      ︸
ubiquitination of p53 by Mdm2
−k3[AT Mp] [p53]Katm + [p53]︸                          ︷︷                          ︸
phosphorylation of p53 by AT Mp
d[p53p]
dt
= k3[AT Mp]
[p53]
Katm + [p53]︸                        ︷︷                        ︸
phosphorylation of p53 by AT Mp
− kdph1[Wip1] [p53p]Kdph1 + [p53p]︸                             ︷︷                             ︸
dephosphorylation of p53p by Wip1
.
(6)
We do not consider p53 gene expression and its mRNA, since, as it has already
been mentioned, the principal means of control on p53 concentration by the cell
is through the degradation of the protein, dominantly through the multiple Mdm2-
dependent ubiquitination [4]. For simplicity, p53 degradation is rather modelled
as an enzymatic reaction and the ubiquitination of p53 in Equation (6) is thus inter-
preted as a loss of mass. Note that although p53 degradation controlled by Mdm2
is a preferential way of p53 degradation reported in cells, natural (dominantly cy-
toplasmic) degradation also occurs, however, with no significant contribution to
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Figure 4.1: Assumptions on the location and exchange of considered proteins
between the nucleus and the cytoplasm made in our model. mRNA variables are
denoted on this figure by the additional subscript RNA, and similarly the subscript
p denotes a phosphorylated protein. The proteins p53 and Mdm2 are assumed
to migrate freely (i.e., without diffusion limitations, resulting in homogeneous
concentrations) within each of the two compartments, nucleus and cytoplasm.
the overall p53 degradation [37, 38]. Thus, in parallel to Mdm2 ubiquitination la-
belling of p53, we add a normal decay term for the degradation of the cytoplasmic
p53.
The genes coding for Mdm2 and Wip1 are expressed in a p53-dependent man-
ner, and we have chosen to model the transcription of these genes quite classically,
by using a Hill function with coefficient 4, since the transcriptionally active p53
appears in tetrameric form [39]. Note that other choices of the coefficient can
be used; however, different Hill coefficients may result in different dynamical re-
sponses of the studied system. Denoting the basal Mdm2 mRNA production rate
kS m, the protein transcription of the Mdm2 gene to its mRNA, Mdm2RNA, can be
written as
d[Mdm2RNA]
dt
= kS m + kS pm
[p53p]4
[p53p]4 + K4S pm︸                   ︷︷                   ︸
Mdm2 gene transcription
. (7)
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The mRNA of Mdm2 then moves to the cytoplasm where it is translated. Trans-
lation is modelled as a linear process with the constant translation rate ktm. Note,
however, that the equations for the cytoplasmic concentrations of mRNAs, Equa-
tion (B.2) in the appendix, describe the concentrations of the unbound mRNAs
present in the cytoplasm. In other words, the mRNA of Mdm2 (similarly, the
mRNA of Wip1) already used in translation is modelled as a loss of the free
mRNA available in the cytoplasm, and thus it is subtracted from the total mRNA.
Produced protein Mdm2 can then freely migrate between the cytoplasm and the
nucleus, and ubiquitinate p53 in both compartments (the equation for p53 in the
cytoplasm is designed in the same way as for the p53 nuclear equation). Regula-
tion of Mdm2 is represented only by considering degradation terms for Mdm2
and Mdm2RNA. The constants kS pm and KS pm are, respectively, p53-dependent
Mdm2 mRNA transcription velocity and Michaelis-Menten p53-dependent Mdm2
mRNA transcription rate.
Transcription and translation of the Wip1 gene run similarly with the corre-
sponding reaction constants kS pw and KS pw , the production rate kS w, and the trans-
lation rate ktw. Note, however, that Wip1 has been observed to be a predominantly
nuclear protein [23]; for this reason, unlike Mdm2, the Wip1 protein has been as-
sumed to move only to, and not from, the nucleus. Phosphatases other than Wip1
that can dephosphorylate ATM and p53 have not been considered in the model.
The compartment-specific physiological roles of the proteins, already men-
tioned in Section 3.4, translate into mathematical simulations in the model that
explicitly take into account cell compartmentalisation. Our assumptions about the
location of these proteins are shown on Figure 4.1.
Most of the kinetic velocities and Michaelis-Menten constants (Table B.1 in
Appendix) appearing in the reactions are taken from the sicentific literature on
the subject [5]; ATM and p53 dephosphorylation rates by Wip1 are taken from
works of Shreeram et al. [15, 16]. Other unknown parameters (in Wip1 expres-
sion, ATM activation) are chosen by exploring the space of parameters so that the
system exhibit oscillatory dynamics for the proteins. These biological observation
facts, together with linear or Michaelis-Menten degradation terms, and boundary
conditions on protein exchanges through the nucleocytoplasmic membrane (their
fluxes being taken as proportional to the differences between averaged nuclear and
cytoplasmic concentrations [5, 6]), finally result in the ODE system that is solved
numerically (equations B.1 and B.2 in Appendix).
17
4.1.3. Short overview of other existing models
There are several mathematical models describing the p53/Mdm2 dynamics,
for example the already mentioned models by Lev Bar-Or et al. [19] which show
(experimentally and numerically) the presence of damped oscillations. The model
developed by Batchelor et al. [14], which is actually based on former models by
Geva-Zatorsky et al. [18], includes only nuclear concentrations of proteins. Ma et
al. [40, 41] use delay differential equations (DDE) to simulate particular delays in
representing the transcription of Mdm2 mRNA and translation of Mdm2 mRNA
into the Mdm2 protein. Their models contain p53 activation by ATM kinase and
only nuclear species are considered.
Ciliberto et al. [42] use the negative feedback p53 → Mdm2 a p53 supple-
mented by a simplified positive feedback to reconstruct p53/Mdm2 oscillations.
In the positive feedback, p53 initiates activation of a cascade of protein interac-
tions (involving PTEN, PIP2, PIP3 and Akt) leading to temporal inhibition of
cytoplasmic Mdm2 translocation to the nucleus. T. Zhang et al. [43] explore the
mechanism of p53/Mdm2 network of [42] and offer three other models simulat-
ing p53/Mdm2 dynamics which combine different positive feedbacks with the
p53/Mdm2 negative feedback. In addition, they propose a mechanism enabling
a cell to decide between cell cycle arrest and apoptosis, assuming that persistent
p53 pulses trigger apoptosis. X.P. Zhang et al. [44] combine results of [42, 43] and
develop a two-phase switch model, which includes p53/Mdm2, ATM/p53/Wip1
and p53/PTEN/Akt/Mdm2 feedbacks, and which can simulate irreversible transi-
tion from cell cycle arrest to apoptosis. Both models of [43, 44] simulating cell
fate decision involve transcription of proarrest and proapoptosis proteins p21 and
p53DINP1 (and other proteins), respectively, the activation of which, however, is
regulated by the p53 affinity for the protein genes, i.e., proarrest proteins are pro-
duced initially in an early cell response phase to DSBs, and proapoptotic proteins
are produced later after a few p53 pulses. Note that the transcriptional regulation
of proteins is modelled by using Hill functions, mostly with coefficients 3 and 4,
in all the mentioned works [40, 41, 42, 43, 44].
There are also some other models simulating p53 signalling network, for ex-
ample, a recently proposed deterministic model by J.K. Kim and T.L. Jackson
[45] with the positive feedback between p53 and Rorα and a model proposed
by K. Puszyn´ski et al. [46] taking stochastic effects into account. Sturrock et
al. [47, 48, 49] and Dimitrio et al. [5, 6] study p53/Mdm2 dynamics, without
Wip1, but using PDE spatial models with exchanges through the nucleocytoplas-
mic membrane, ATM being considered in Dimitrio et al. as a bifurcation parame-
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Figure 4.2: (a) Nuclear ATM/p53/Mdm2/Wip1 oscillations over a 24 hour-long
time interval. (b) Evolution of the ATM monomerisation and dimerisation with
the total concentration of ATM, AT MTOT (0) = 1.3µM, and [E] = 0.1µM (where E
is a hypothetical damage signalling molecule launching ATM activation). Plotted
concentrations are dimensionless.
ter; both models exhibit sustained oscillations for p53.
4.2. Numerical simulations and discussion
4.2.1. The ODE model reproduces the pulsatile behaviour of proteins
Under specified circumstances, the model ODE system yields expected pul-
satile behaviour for the proteins. Pulses of the involved proteins are illustrated
on Figure 4.2. Figure 4.2(a) confirms that the model can be used to reconstruct
experimental observations [14]. After DNA damage producing a (likely molec-
ular) signal E with concentration [E] = 0.1µM (in this particular simulation),
ATM is firstly activated. Then AT Mp phosphorylates p53 and thus, the peak on
the curve of p53p evolution is observed later than the peak of AT Mp. Mdm2 and
Wip1 are the targets of active p53p, hence the corresponding peaks appear after
the p53 peak. Mdm2 and Wip1 then regulate p53, which leads to p53p dephos-
phorylation and degradation. Wip1 also dephosphorylates AT Mp with formation
of ATM dimers. The period of the first pulse for nuclear p53p is ∼5.16 hours and
for AT Mp, it is ∼4.4 hours, which fits experimental observations [14, 17]. ATM
evolution can be seen on Figure 4.2(b). The amount of activated AT Mp at the
peaks of the evolution curve exceeds 50% of all ATM protein, as has been ob-
served in biological experiments [24]. Note that the total concentration of ATM is
set to AT MTOT = 1.3µM in this simulation.
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Figure 4.3: Phase plane curves relative to the involved nuclear proteins with [E] =
0.1µM (where E is a hypothetical damage signalling molecule launching ATM
activation): (a) AT Mp and p53p (b) Mdm2 and p53p.
The pulses of the proteins on Figure 4.2 are, apart from a couple of first pulses,
of the same amplitude, i.e., the model quickly produces sustained (undamped)
oscillations [14, 17]. This can be seen from the phase plane Figures 4.3 (and
Figures E.1 in the Appendix), showing orbits of the solutions fastly converging
toward stable limit cycles. The first pulses on Figure 4.2(a) are of higher ampli-
tude mainly because of the choice of initial concentrations of proteins; all initial
concentrations of proteins are set to be zero in our simulations, and since Wip1
and Mdm2 are not initially present in the cell, the concentrations of p53 and ATM
increase until the regulators Wip1 and Mdm2 start to accumulate in the nucleus
and thus inhibit further p53 and ATM production.
The proposed ODE model is “noise-free” and we do not consider stochasticity
in protein gene expression, nor noise in protein production rates. The ampli-
tudes of experimentally observed pulses in the extended research works of Geva-
Zatorsky et al. [18] are found to vary widely from peak to peak and from cell to
cell (even within the same irradiation dose), mainly due to noise in protein produc-
tion rates. It is also worth mentioning that the periods of biologically measured
oscillations are affected by noise, so that the duration of one pulse may be differ-
ent from another; however, this difference comes with a variability of (at most)
20% in contrast to the 70% variability in amplitudes [18]. Our ODE model shows
variability in periods in the first couple of pulses, simulated with [E] = 0.1µM
(Figure E.2(a) in the Appendix). The first pulse is of length 5.16 hours, the period
of the stable limit cycle for [E] = 0.1µM is ∼6 hours. We leave the study of the
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impact of noise on oscillations for further modelling works.
4.2.2. Bifurcation analysis of the system reveals two supercritical Hopf bifurca-
tion points that correlate with DNA damage levels
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Figure 4.4: (a) Pair of eigenvalues crossing the imaginary axis for [E] = 2.5×10−5
and [E] = 0.97 and thus revealing Hopf bifurcation points. (b) Evolution of
the period of the stable limit cycles occurring between the two Hopf bifurcation
points; [E] is in logarithmic scale.
With [E] = 0 we can easily calculate the equilibrium point of the studied sys-
tem (not shown). Forward continuation, using the Matlab package MatCont [50],
of the equilibrium curve starting from the previously computed equilibrium point,
numerically reveals two Hopf bifurcation points with negative Lyapunov coeffi-
cients [51] p. 120, i.e., corresponding to supercritical Hopf bifurcations. These
Hopf bifurcation points are obtained for the values [E]1 = 2.5 × 10−5µM and
[E]2 = 0.97µM. Note that the computed equilibria are hyperbolic, [51] p. 67, ex-
cept for the two Hopf bifurcation points, since the Jacobian matrix of the system
has eigenvalues with non-zero real parts for all values of [E] except [E]1 and [E]2.
A special situation appears in case of the Hopf points where a pair of complex
eigenvalues crosses the imaginary axis, see Figure 4.4(a). For values below [E]1
the equilibrium of the system is stable (all eigenvalues have negative real parts)
and the concentrations of proteins tend to their steady states very quickly. By
passing through this value, the equilibrium becomes unstable (the pair of com-
plex eigenvalues crossing the imaginary axis change the real parts from negative
to positive) and stable limit cycles appear; the equilibrium of the ODE system is
stable again for [E] > [E]2 (all eigenvalues have negative real parts again).
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The periods of the stable limit cycles vary between 5.92 and 6.26 hours with
varying [E], as illustrated on Figure 4.4(b). Bifurcation diagrams of p53p with re-
spect to E, p53p/AT Mp, p53p/Mdm2 and p53p/AT Mp are plotted on Figures 4.5.
The amplitudes of p53p and AT Mp of the stable limit cycles are small for values
of [E] close to [E]1 and [E]2, respectively (as expected in the case of supercritical
Hopf bifurcations), which is illustrated on Figures 4.5(a) and 4.5(b). This does
not, however, mean that the amplitudes of concentrations are of such small values
throughout the whole time period. In fact, it may take several days until the limit
cycle is reached; compare, for example, Figures 4.5(a) with 4.6(a) and 4.6(b).
In our ODE settings, E is considered as the measure of DNA damage. Inter-
esting situations appear whenever E is small and close to the first Hopf bifurcation
point (which may correspond to a few DSBs only) and when E is very big (which
may correspond to serious DNA damage and many DSBs). In the first case, the
AT Mp solutions do not even oscillate for the values of [E] ≈ [E]1. The ATM
trajectories then tend to steady states with low values; however, these small con-
centrations of AT Mp can still elicit p53p pulses, see Figure 4.6(a). This may
contradict experimental observations that show ATM oscillations accompanying
p53 oscillations after DNA damage [14]; note, however, that those experiments
were performed with exposure of cells to 10 Gy of γ-irradiation and did not con-
sider that DNA damage can cause only a few DSBs (and which may correspond to
[E]1). On the other hand, other works show evidence that only very small amounts
of ATM (even not detectable) can still elicit actual p53 signalling [22, 26]. Indeed,
DNA damage at [E] ≈ [E]1 may correspond to occasional DNA DSBs which do
not need ATM for DNA repair and only moderate ATM is produced which is still
efficient in p53 activation.
ATM oscillations are damped and disappear for [E] greater than [E]2: once the
oscillations have vanished, they do not appear again with further increasing values
of [E]. Figure 4.6(b), for example, shows the protein dynamics for [E] = 10µM.
In this case ATM is almost fully activated and only small deviations in ATM con-
centration can be seen. Hence, we can speculate that if it is impossible to re-
pair DNA DSBs, then phosphatase activities on ATM are inhibited, active ATM
achieves its maxima and apoptosis is initiated. However, the latter suggestion is
not supported by experimental observations; in fact, there is no paper in the liter-
ature, to our best knowledge, clarifying ATM activity and location in single cells
committing apoptosis. Thus, ATM oscillates whenever it is necessary for a proper
cell response to DNA damage of an alive cell, and once [E] becomes too high, os-
cillations disappear and the cell is sent to apoptosis and dies. Such interpretation,
however, requires E to be dependent not only on DNA damage levels but also
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Figure 4.5: (a) Bifurcation diagram for nuclear p53p, (b) bifurcation diagram for
nuclear AT Mp with respect to E = [E], E is in logarithmic scale. Bars plotted
on figures are the heights (showing maximum and minimum) of the amplitudes
of stable limit cycles. (c) p53p/Mdm2 limit cycles occurring for values of the
damage signal E between the two Hopf bifurcation points. (d) The same in the
p53p/AT Mp phase plane. Plotted concentrations are dimensionless. The equilib-
rium curves in (c) and (d) are the curves joining the two Hopf bifurcation points
H, constituting stable, then unstable, and then stable equilibrium branch again,
with the stable limit cycles surrounding the unstable equilibrium points.
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Figure 4.6: (a) Nuclear p53p/AT Mp concentrations from the ODE system for
[E] = [E]1 = 2.5×10−5µM. The concentration of AT Mp converges to the equilib-
rium point and the concentration of p53p tends to a stable limit cycle. (b) Nuclear
AT Mp/p53p/Mdm2/Wip1 concentrations for [E] = 10µM. The concentration
of AT Mp is of small amplitude, getting even smaller with further increasing [E].
Plotted concentrations are dimensionless, AT MTOT (0) = 1.3µM.
on other factors amplifying the abundance of E, possibly with the contribution
of proapoptotic proteins. Indeed, Figure 4.6(b) still shows (damped) p53 pulses,
initially of higher amplitudes, that can act transcriptionally on its substrates.
4.2.3. Two negative feedback loops and a compartmental distribution of cellular
processes produce sustained oscillations
In order to prove that the oscillating ATM protein plays an active role in
achieving p53 pulses we made several simulations to test different possibilities
and thus we explored the system in more details. For example, the model can
be used to mimic the observed inhibition of p53/Mdm2 pulses following one full
ATM pulse [14]; this is illustrated on Figures 4.7, where ATM is inhibited after
one pulse. We can see the complete first pulses of ATM, p53, Mdm2 and Wip1,
among which protein Wip1 blocks further ATM activation (in the corresponding
equation (4) of ATM dephosphorylation by Wip1, the Michaelis-Menten constant
Kdph2 is set to be very small, Kdph2 = 0.0001). Although the first pulses of the
p53 and Mdm2 proteins are induced, they are not sufficient to produce subsequent
pulses after ATM dissociation is blocked.
Other tests when we inhibit, respectively,
• the negative feedback Wip1 a AT M (kdph2 = 0 in (4), Figure E.3(a) in
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Figure 4.7: (a) The nuclear ATM/p53/Mdm2/Wip1 dynamics over a 24 hour-long
time interval following ATM inhibition after one full pulse. (b) Evolution of
the ATM monomerisation and dimerisation with the total concentration of ATM,
AT MTOT (0) = 1.3µM, and [E] = 0.1µM, following ATM inhibition after one full
pulse. Plotted concentrations are dimensionless.
Appendix),
• the positive feedback AT M → p53 (k3 = 0 in (6), Figure E.3(b)),
• the negative feedback Wip1 a p53p (kdph1 = 0 in (6), Figure E.3(c)),
• the positive feedback p53p → Wip1 (kS pw = 0, Figures E.3(d) and (e)),
produce either damped oscillations or do not produce oscillations at all. The ATM
and Wip1 proteins must thus be involved in the p53/Mdm2 dynamics in order to
produce sustained p53 oscillations.
The p53/Mdm2 negative feedback cannot be omitted either, since the inhibi-
tion of Mdm2 activity on p53 (k1 = 0 in (6), see Figure 4.8(a)) or the inhibition
of the transcriptional activity of p53p on Mdm2 (kS pm = 0 in (7), Figures E.3(f)),
does not produce oscillations.
We can further ask whether the two feedback loops without strict location of
proteins in the compartments can lead to p53 oscillations. Merging protein dy-
namics into one compartment (the whole cell), i.e. omitting exchange of proteins
between the nucleus and the cytoplasm but rather considering both compartments
as the one where proteins and their mRNA can freely migrate, is not, however,
sufficient in producing sustained oscillations. Figure 4.8(b) shows evolution of
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protein concentrations in the case [E] = 0.1µM. As in the case shown on this
figure, all other choices of [E] exhibit concentrations of proteins converging to
their steady states (bifurcation analysis does not reveal any significant point). The
role of compartmentalisation in p53 dynamics has been studied in more details in
another research work [5, 52].
Hence, the feedbacks p53 → Mdm2 a p53 and AT M → p53 → Wip1 a
AT M together with compartmental distribution of proteins result in sustained os-
cillations, and neglecting any part of these three components fails to produce sus-
tained oscillations.
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Figure 4.8: (a) The ATM/p53/Mdm2/Wip1 dynamics over a 24 hour-long time
interval, [E] = 0.1µM, in a case when Mdm2-mediated ubiquitination of p53
is inhibited, k1 = 0. (b) The ATM/p53/Mdm2/Wip1 dynamics over a 24 hour-
long time interval and [E] = 0.1µM in a case when only one compartment is
considered.
4.2.4. ATM threshold required for initiation of p53 pulses
Note again that there are two significant points in the range of the signal E,
the two Hopf bifurcation points, [E]1 = 2.5 × 10−5µM and [E]2 = 0.97µM in
the presented simulation settings: values of E starting from [E]1 are sufficient
to elicit sustained oscillations in the p53 protein nuclear concentrations, and the
second Hopf bifurcation point [E]2 is the critical point at which stable limit cycles
(otherwise said, sustained oscillations of the proteins) disappear. This point thus
may mark a decision for the cell not to go on in DNA DSBs repairing processes,
and rather to start apoptosis. A relation to a supposed apoptotic threshold [1]
remains however to be further established.
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The hypothetical signal E is supposed to be produced by DNA DSB sensors
and/or by changes in chromatin structure, and may be affected by other factors like
the MRN complex bound to the DNA break sites and the presence of proarrest
and proapoptotic proteins. Then E is delivered to ATM dimers and promotes
ATM activation. Interestingly, an amount of E as small as [E]1 can, for a value
of the total ATM protein AT MTOT = 1.3µM, activate ATM at the concentration
∼0.02µM, Figure 4.6(b), that is sufficient to produce oscillations in p53.
Note, however, that the Hopf bifurcation points are dependent on the total
concentration of nuclear ATM, AT MTOT . Indeed, Figure 4.9(a) shows the evo-
lution of the Hopf bifurcation points with respect to AT MTOT (on the y-axis).
We can see that the values of [E]1 do not change dramatically and they range
between 1, 17 × 10−5 (which corresponds to AT MTOT = 10µM) and 3.5 × 10−5
(which corresponds to AT MTOT = 0.78µM). The dependence of [E]2 on AT MTOT
seems to be more intriguing. Similarly to [E]1 the Hopf bifurcation points [E]2
increase with decreasing AT MTOT , and asymptotically reach values correspond-
ing to AT MTOT ≈ 0.77µM, Figure 4.9(a). In other words, the system has two
Hopf bifurcation points for AT MTOT > 0.77µM (with similar bifurcation dia-
grams between these points Figure 4.9(b)); the only one Hopf bifurcation point
∼3.8 ×105 below AT MTOT = 0.77µM determining stable solution and unstable
solution (stable limit cycle). The system does not have any Hopf bifurcation point
for AT MTOT < 0.082µM.
Interestingly, for all the [E]1 values corresponding to different AT MTOT , the
concentration in activated ATM protein always reaches the steady-state value
0.02µM (not shown). This helps resolve a biological unanswered question; in
particular, it has been observed that only a fraction of ATM molecules can be suf-
ficient to initiate proper cell responses to DNA damage [22]; however, a certain
threshold for initial ATM concentration is supposed to exist (but it is not speci-
fied) to initiate the ATM signalling pathway [14]. Thus, the analysis of our model
reveals that the threshold for ATM, which is independent of the total nuclear ATM
proteins, can be 0.02µM (in our model constant settings).
5. Conclusion
Explaining experimentally observed p53 oscillations in human cancer cells
after exposure of the cells to γ-irradiation [14, 17, 18] is a mathematical mod-
elling challenge, especially in the perspective of proposing p53-mediated anti-
cancer drug-induced cell cycle arrest/apoptotic predictions. This paper is the ex-
tension of a previous work by Dimitrio et al. [5, 6]. It presents the dynamics of the
27
(a)
−6 −4 −2  0
0
2
4
6
8
10
log10 E
AT
M T
O
T
[E]2
[E]1 [E]2
[E]1
 
 
(b)
−5
 0
0
5
10
0
0.5
1
1.5
2
H 
log10 E
H 
H 
H 
ATMTOT
p5
3 p
Figure 4.9: (a) The evolution curves of both Hopf bifurcation points (curves in
brown and black colours). The Hopf bifurcation points [E]1 and [E]2 are com-
puted for AT MTOT = 10µM, the points [E]1 and [E]2 for AT MTOT = 0.78µM.
The concentration E = [E] is in the logarithmic scale. (b) Bifurcation diagrams
of p53p with respect to changing AT MTOT and [E].
“guardian of the genome” p53, that plays essential parts in cell responses to DNA
damage and checkpoint signalling. The spatial distribution of proteins in a cell is
taken into account and it is shown that such compartmental recognition of cellular
events allows to reconstruct the pulsatile behaviour of proteins without the need
to introduce any time delay in their dynamics.
The oscillatory dynamics of the involved proteins can be speculatively ex-
plained as periodical testing of the presence of DNA damage; if unrepaired DNA
DSBs still exist, additional pulses of both phosphorylated ATM and p53 are trig-
gered. More precisely, we propose the following interpretation: the level of phos-
phorylated ATM increases in response to DSBs and is then reduced due to the in-
crease of the p53 concentration (since ATM phosphorylation of p53 leads to p53
stabilisation, which, afterwards, activates Wip1, that inactivates ATM). When p53
levels are in turn reduced by the interaction with Mdm2 (after p53 dephosphory-
lation by Wip1), ATM is released to re-examine the DNA. If the number of breaks
remains above a certain threshold, the pathway becomes reactivated, leading to a
second pulse of ATM and p53, and this continues until the number of DNA breaks
is dropped below the threshold, or the cell decides to start apoptosis [14].
The original models of Dimitrio et al. [5, 6] involve ATM as a direct mea-
sure of DNA damage, in the form of a parameter that remains constant in the
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studied time interval. It has been experimentally shown, however, that a pulsatile
behaviour for p53/Mdm2 cannot be achieved without oscillations of ATM [14].
In addition, there exist biological studies that confirm a role for ATM in cancer
cell apoptosis induced, for example, by ionising radiations [53]. Hence, in this ex-
tended modelling work, we consider ATM as an essential part of the DNA damage
signalling pathway, varying with time, that after ATM dimer dissociation and ac-
tivation, phosphorylates p53 and thus initiates p53 transcriptional activity towards
proarrest and proapoptotic genes (for example, p21 and 14-3-3σ on the proarrest
side, and Pig3, Apaf1 and PUMA on the proapoptotic side).
The p53 protein responds to a variety of cellular stresses (such as those causing
DNA strand breaks, e.g., cytotoxic drug insults) through the transcription mode
of protein production. Despite the complexity of all signalling pathways occur-
ring in the stressed cells and the production of proteins involved therein, we can
conclude that the pathway including p53 activation can be successfully recon-
structed by our compartmental model that, in particular, takes into account the
ATM/p53/Mdm2/Wip1 pulsatile dynamics as has been observed in the scientific
literature on the subject [14, 15, 24, 26], and as is summarised in details in the
biological background part of the present work.
In an even more realistic vision of the processes leading a single cell to de-
cision between survival and death, more than on deterministic events, random
molecule encounters and stochastic gene expression should be taken into consid-
eration, and should be modelled by stochastic processes (as sketched in [49] for
Hes1), from which deterministic equations (partial differential equations physi-
ologically structured in variables, identified as biological “readouts” in a single
cell model, representing relevant biological variability inside the cell population)
should be further designed at the level of cell populations.
In the same way, in the perspective of connecting the proposed p53 modelling
with existing PK–PD models, drug effects, measured only at the cell popula-
tion level, can be represented as environmental factors exerting their influence
on molecular targets, included as functions in stochastic processes, at the level of
a single cell. Establishing such connections between stochastic events at the indi-
vidual cell level and resulting deterministic effects at the cell population level is
a challenge for mathematical modelling that we intend to tackle in future works.
Readers interested in such interconnections between stochastic and deterministic
mathematics in the Hes1 regulatory network are recommended to read the papers
by M. Sturrock et al. [49, 56] to get acquainted with this challenge, a considerable
one in the most general case.
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Appendix A. Equations for ATM dynamics
Following in vivo observations [24], ATM is activated very shortly after DNA
damage in the nucleoplasm, i.e., with no need of ATM binding DNA damage
sites, through the dissociation of the inactive ATM dimers, AT MD, into the active
monomers, AT Mp. The activation signal is however not biologically specified; it
is assumed to be produced by changes in chromatin after DNA damage [24, 27],
amplified by MRN complex (sensor of DNA DSBs) [54], or this signal may be
actually the MRN complex itself and its interaction with ATM [55]. Although
there is not a general agreement among biologists, ATM is mostly thought to be
activated very promptly. We thus represent ATM activation through its interaction
with an unknown signal, likely a molecule or the result of a chain of molecular
reactions, denoted by E, which is assumed to be constant in a very short time
interval, so that the reaction of E with ATM dimers can be written as the enzymatic
reaction, Equation (2), i.e.
E + AT MD
ki

k−i
Complex
kph2−→ 2 AT Mp + E. (A.1)
Dephosphorylation (and deactivation) of ATM monomers is observed through the
interaction of AT Mp with Wip1 [14, 15, 16], Equation (3), i.e.
Wip1 + 2 AT Mp
k j


k− j
Complex
kdph2−→ AT MD + Wip1. (A.2)
By applying the law of mass action and the quasi-steady-state approximation,
the loss of AT MD derived from the first reaction (A.1) can be written in the form
d[AT MD]
dt
= −kph2[E] [AT MD]Kph2 + [AT MD] . (A.3)
However, the equation for the loss of AT Mp is not so straightforward, since as
a substrate we now have two AT Mp proteins. Let us write
s = [AT Mp], e = [Wip1], p = [AT MD] and c = [Complex]
for the concentrations of the reactants in (A.2). Then the law of mass action
applied to (A.2) leads to the following equation for the substrate s,
ds
dt
= −2k js2e + 2k− jc, (A.4)
30
since in every c that is made, two of s are used, and every time c is degraded, two
of s are produced; and for the other reactants,
de
dt
= −k js2e + (k− j + kdph2)c,
dc
dt
= k js2e − (k− j + kdph2)c,
dp
dt
= kdph2c.
(A.5)
The initial conditions are e(0) = e0, s(0) = s0 and c(0) = p(0) = 0. With the
conservation property of the enzyme e, dedt +
dc
dt = 0, and so with e(t) = e0 − c(t),
we have the system of ordinary differential equations (ODEs) reduced to
ds
dt
= −2k js2(e0 − c) + 2k− jc,
dc
dt
= k js2(e0 − c) − (k− j + kdph2)c.
(A.6)
The quasi-steady-state approximation then assumes dcdt ≈ 0. Hence, from the
second equation in (A.6) we can explicitly write c in terms of s, in particular,
c =
e0s2
s2 + Kdph2
(A.7)
where Kdph2 =
k− j+kdph2
k j
is the Michalis-Menten rate of reaction. Substituting c in
the equation for s, we finally can write
ds
dt
= −2e0kdph2 s
2
s2 + Kdph2
, (A.8)
where in numerical simulations e0 is replaced by e.
By coming back to our original problem reaction (A.2), we get the equation
for the loss of AT Mp,
d[AT Mp]
dt
= −2kdph2[Wip1] [AT Mp]
2
[AT Mp]2 + Kdph2
. (A.9)
Finally, the combination of (A.3) and (A.9) can fully describe ATM activation
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and deactivation. In particular, equations of interest are
d[AT MD]
dt
= −kph2[E] [AT MD]Kph2 + [AT MD] + kdph2[Wip1]
[AT Mp]2
Kdph2 + [AT Mp]2
,
d[AT Mp]
dt
= 2kph2[E]
[AT MD]
Kph2 + [AT MD]
− 2kdph2[Wip1] [AT Mp]
2
Kdph2 + [AT Mp]2
,
(A.10)
since the production of AT MD is half of AT Mp. Note that we do not consider
ATM in inactive monomeric state.
Note that it is, however, not necessary to use both equations in numerical sim-
ulations, and actually, we cannot use both of them, since the Jacobian matrix of
the ODE system composed of all other equations describing the p53/Mdm2 dy-
namics, see Appendix B, is singular for [E] = 0, i.e. for the value for which
the system achieves equilibrium. This is because the derivative of the right-hand
side of the first equation in (A.10) with respect to the variable [AT MD] is zero
for [E] = 0, similarly the derivatives of all other right-hand sides of the equations
describing the dynamics of proteins are zeros as well (simply because these equa-
tions do not contain [AT MD], i.e. they are constants with respect to [AT MD]);
see the equations in (B.1) and (B.2). To calculate the equilibrium for [E] = 0 is
a straightforward algebraic exercise; the problem, however, is in the continuation
of the equilibrium curve starting at the computed equilibrium for [E] = 0, since
continuation techniques require non-singular Jacobian matrices.
By recalling the conservation property of the ATM protein, i.e. [AT Mp] +
2[AT MD] = const = AT MTOT [µM] and thus by writing [AT MD] = 12 (AT MTOT −
[AT Mp]) in the second equation in (A.10), we actually have the mathematical
equation for [AT Mp] in the form
d[AT Mp]
dt
=2kph2[E]
1
2 (AT MTOT − [AT Mp])
Kph2 + 12 (AT MTOT − [AT Mp])
− 2kdph2[Wip1] [AT Mp]
2
Kdph2 + [AT Mp]2
.
(A.11)
The conservation property observed by Bakkenist and Kastan [24] claims (almost)
non-changing concentration of the total ATM proteins. Note that ATM is not
observed to be degraded in the cell and since it is the 370 kDa large protein, its
inactivation through the dimerisation instead of degradation is energetically more
profitable.
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Appendix B. The ODE system
Section 4.1 contains the description of all processes and reactions which we
have considered in the model. All the mentioned facts can be collected in the
following equations, divided into those describing events occurring, respectively,
in the nucleus and in the cytoplasm, Equations (B.1) and (B.2).
Protein exchange fluxes are modelled as linear contributions of the differences
between averaged nuclear and cytoplasmic concentrations precisely determined
by the permeability rates, see, for example, the term ppVr([p53](n) − [p53](c)) in
the first equation of (B.1). Here, Vr is a special volume ratio introduced in [42]
to underline the fact that reactions are Vr-times faster in the nucleus than in the
cytoplasm provided that the nucleus is Vr-times smaller than the cytoplasm, and
pp is the permeability coefficient for p53 [5, 6].
(N)

d[p53](n)
dt
= kdph1[Wip1](n)
[p53p](n)
Kdph1 + [p53p](n)
− k1[Mdm2](n) [p53]
(n)
K1 + [p53](n)
− k3[AT Mp](n) [p53]
(n)
Katm + [p53](n)
− ppVr([p53](n) − [p53](c)),
d[Mdm2](n)
dt
= −pmVr([Mdm2](n) − [Mdm2](c)) − δm[Mdm2](n),
d[Mdm2RNA](n)
dt
= kS m + kS pm
([p53p](n))4
K4S pm + ([p53p]
(n))4
− pmRNAVr[Mdm2RNA](n)
− δmRNA[Mdm2RNA](n),
d[p53p](n)
dt
= k3[AT Mp](n)
[p53](n)
Katm + [p53](n)
− kdph1[Wip1](n) [p53p]
(n)
Kdph1 + [p53p](n)
,
d[AT Mp](n)
dt
= 2kph2[E]
1
2 (AT MTOT − [AT Mp](n))
Kph2 + 12 (AT MTOT − [AT Mp](n))
− 2kdph2[Wip1](n) ([AT Mp]
(n))2
Kdph2 + ([AT Mp](n))2
,
d[Wip1](n)
dt
= pwVr[Wip1](c) − δw[Wip1](n),
d[Wip1RNA](n)
dt
= kS w + kS pw
([p53p](n))4
K4S pw + ([p53p]
(n))4
− pwRNAVr[Wip1RNA](n)
− δwRNA[Wip1RNA](n),
(B.1)
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(C)

d[p53](c)
dt
= kS − k1[Mdm2](c) [p53]
(c)
K1 + [p53](c)
− pp([p53](c) − [p53](n)) − δp[p53](c),
d[Mdm2](c)
dt
= ktm[Mdm2RNA](c) − pm([Mdm2](c) − [Mdm2](n)) − δm[Mdm2](c),
d[Mdm2RNA](c)
dt
= pmRNA[Mdm2RNA](n) − ktm[Mdm2RNA](c) − δmRNA[Mdm2RNA](c),
d[Wip1](c)
dt
= ktw[Wip1RNA](c) − pw[Wip1](c) − δw[Wip1](c),
d[Wip1RNA](c)
dt
= pwRNA[Wip1RNA](n) − ktw[Wip1RNA](c) − δwRNA[Wip1RNA](c),
(B.2)
All numerical results presented in the text are, if it is not specified otherwise,
produced by simulations with the constants listed in Table B.1.
Appendix C. Equations for a one-compartment model
In Section 4.2.3 we show that the two negative feedbacks together with the
compartmental distribution of cell events are necessary to elicit protein pulses. In
particular, Figure 4.8(b) confirms the need for two compartmental model. The
system of equations which is tested in this one-compartmental model is in (C.1).
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Parameter Chosen Value Units Description
kdph1 78 min−1 Wip1-dependent p53 dephosph. velocity
Kdph1 25 µM Mich.-Men. rate of Wip1-dependent p53 dephosph.
k3 3 min−1 p53 phosphorylation velocity
Katm 0.1 µM Mich.-Men. rate of p53 phosph.
k1 10 min−1 p53 ubiquitination velocity
K1 1.01 µM Mich.-Men. rate of p53 ubiq.
pp 0.083 min−1 p53 permeability
Vr 10 adim Volume ratio
pm 0.04 min−1 Mdm2 permeability
δm 0.16 min−1 Mdm2 degradation rate
kS m 0.005 µM/min Basal Mdm2 RNA transcription rate
kS pm 1 µM/min Mdm2 RNA transcription velocity
KS pm 0.1 µM Mich.-Men. rate of Mdm2 RNA trans.
pmRNA 0.083 min−1 Mdm2 RNA permeability
δmRNA 0.0001 min−1 Mdm2 RNA degradation rate
ktm 1 min−1 Mdm2 translation rate
kS 0.015 µM/min Basal p53 synthesis rate
δp53 0.2 min−1 p53 degradation rate
pw 0.083 min−1 Wip1 permeability
δw 0.2 min−1 Wip1 degradation rate
kS w 0.03 µM/min Basal Wip1 RNA transcription rate
kS pw 1 µM/min Wip1 RNA transcription velocity
KS pw 0.1 µM Mich.-Men. rate of Wip1 RNA trans.
pwRNA 0.083 min−1 Wip1 RNA permeability
δwRNA 0.001 min−1 Wip1 RNA degradation rate
ktw 1 min−1 Wip1 translation rate
kdph2 96 min−1 Wip1-dependent ATM dephosph. velocity
Kdph2 26 µM Mich.-Men. rate of Wip1-dependent ATM dephosph.
kph2 15 min−1 ATM phosphorylation velocity
Kph2 1 µM Mich.-Men. rate of ATM phosph.
[E] 0.1 µM Concentration of “the damage signal”
AT MTOT 1.3 µM Total ATM concentration
Table B.1: Parameter values for the ODE model (B.1) and (B.2).
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
d[p53]
dt
= kS + kdph1[Wip1]
[p53p]
Kdph1 + [p53p]
− k1[Mdm2] [p53]K1 + [p53]
− k3[AT Mp] [p53]Katm + [p53] − δp[p53],
d[Mdm2]
dt
= ktm[Mdm2RNA] − δm[Mdm2],
d[Mdm2RNA]
dt
= kS m + kS pm
([p53p])4
K4S pm + ([p53p])
4
− δmRNA[Mdm2RNA] − ktm[Mdm2RNA],
d[p53p]
dt
= k3[AT Mp]
[p53]
Katm + [p53]
− kdph1[Wip1] [p53p]Kdph1 + [p53p] ,
d[AT Mp]
dt
= 2kph2[E]
1
2 (AT MTOT − [AT Mp])
Kph2 + 12 (AT MTOT − [AT Mp])
− 2kdph2[Wip1] ([AT Mp])
2
Kdph2 + ([AT Mp])2
,
d[Wip1]
dt
= ktw[Wip1RNA] − δw[Wip1],
d[Wip1RNA]
dt
= kS w + kS pw
([p53p])4
K4S pw + ([p53p])
4
− δwRNA[Wip1RNA] − ktw[Wip1RNA],
(C.1)
Appendix D. Matlab code
function ODEp53Mdm2ATMWip1system
% ... solves the ODE system (B.1) and (B.2) written in ODEs.m (below),
% The ODE system involves ATM/p53/Mdm2/Wip1 protein dynamics.
%
% This function returns the evolution of proteins’ concentrations in the
% time interval of 24 hours. Output are Figures 4.2(a) and (b).
% To get other plots of concentrations (Figures 4.6, 4.7, 4.8 and E.3),
% please, change the constants as they are specified in the paper
% (or as you wish if you are interested in other sorts of plots).
% Note, however, that setting some parameters to zero may lead to
% collisions with nondimensionalisation of variables (e.g. division by
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% zero and thus to incorrect results)!
%
% Note, that the bifurcation analysis of the system is done through the
% Matlab package MatCont.
timeint = [0,1440]; % time interval
initcond = zeros(12 ,1); % initial conditions
ATMtot = 1.3; % total concentration of ATM proteins (monomers and dimers)
E = 0.1; % signal produced by DNA damage
% solve ODE
[t,baru] = ode45(@(t,u) ODEs(t,u,ATMtot,E),timeint,initcond);
% plot solutions (Figures 4.2)
figure;
axes(’FontSize’,14);
plot(t,(ATMtot-baru(:,7))/2,’Color’,[0 0.5 1],’LineWidth’,2, ...
’DisplayName’,’[ATM_D]’);
hold on;
plot(t,baru(:,7),’Color’,[1 0 0],’LineWidth’,2, ...
’DisplayName’,’[ATM_p]’);
hold off;
xlabel(’time (hrs)’,’FontSize’,14);
set(gca,’XTickLabel’,{’0’,’6’,’12’,’18’,’24’},’XTick’,[0 360 720 1080 1440]);
ylabel(’dimesnionless concentration’,’FontSize’,14);
legend(’show’);
figure;
axes(’FontSize’,14);
plot(t,baru(:,7),’Color’,[1 0 0],’LineWidth’,2, ...
’DisplayName’,’[ATM_p]^{(n)}’);
hold on;
plot(t,baru(:,4),’Color’,[0 1 0],’LineWidth’,2, ...
’DisplayName’,’[p53_p]^{(n)}’);
plot(t,baru(:,2),’Color’,[0 0 1],’LineWidth’,2, ...
’DisplayName’,’[Mdm2]^{(n)}’);
plot(t,baru(:,5),’Color’,[0 0 0],’LineWidth’,2, ...
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’DisplayName’,’[Wip1]^{(n)}’);
hold off;
xlabel(’time (hrs)’,’FontSize’,14);
set(gca,’XTickLabel’,{’0’,’6’,’12’,’18’,’24’},’XTick’,[0 360 720 1080 1440]);
ylabel(’dimensionless concentration’,’FontSize’,14);
legend(’show’);
end
% the ODE system
function du = ODEs(t,u,ATMtot,E)
% the system’s constants, for the full description see Table B.1
k3=3; Katm=0.1;
kdph1=78; Kdph1=25;
k1=10; K1=1.01;
pp=0.083; Vr=10;
pm=0.04; deltam=0.16; kSm=0.005; kSpm=1; KSpm=0.1; pmrna=0.083;
deltamrna=0.0001; ktm=1;
kS=0.015; deltap=0.2;
pw=0.083; deltaw=0.2; kSw=0.03; kSpw=1; KSpw=0.1; pwrna=0.083;
deltawrna=0.001; ktw=1;
kph2=15; Kph2=1;
kdph2=96; Kdph2=26;
% nondimensionalisation of the variables is done so that the term relative to
% the main bifurcation parameter E depends on as small possible number of
% parameters as possible. Other choices are, of course, possible.
barE = E/Kph2;
ts=1/kph2;
alpha1=Katm; alpha4=alpha1; alpha2=kSpm/k3; alpha3=alpha2;
alphav1=Kph2; alphav2=alphav1;
alphaw1=kSpw/k3*10; alphaw2=alphaw1;
barkdph1 = ts*kdph1*(alphaw1/alpha1); barKdph1 = Kdph1/alpha4;
bark1 = ts*k1*(alpha2/alpha1); barK1 = K1/alpha1;
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bark3 = ts*k3*(alphav2/alpha1); barKatm = Katm/alpha1;
barpp=ts*pp; barpm=ts*pm; bardeltam=ts*deltam;
barkSm=ts*kSm/alpha3; barkSpm=ts*kSpm/alpha3; barKSpm=KSpm/alpha4;
barpmrna=ts*pmrna; bardeltamrna=ts*deltamrna;
barpw=ts*pw; bardeltaw=ts*deltaw;
barkSw=ts*kSw/alphaw2; barkSpw=ts*kSpw/alphaw2; barKSpw=KSpw/alpha4;
barpwrna=ts*pwrna; bardeltawrna=ts*deltawrna;
barkdph2=ts*kdph2*(alphaw1/alphav2); barKdph2=Kdph2/(alphav2^2);
barkS=ts*kS/alpha1; bardeltap=ts*deltap;
barktm=ts*ktm; barktw=ts*ktw;
ATMtot=ATMtot/alphav1;
% solve du/dt = f(t,u)
du = zeros(12,1);
% equations for the nucleus (B.1)
% p53
du(1)=barkdph1*u(5)*(u(4)/(barKdph1+u(4)))-bark1*u(2)*(u(1)/(barK1+u(1))) ...
-bark3*u(7)*(u(1)/(barKatm+u(1)))-barpp*Vr*(u(1)-u(8));
% Mdm2
du(2)=-barpm*Vr*(u(2)-u(9))-bardeltam*u(2);
% Mdm2 mRNA
du(3)=barkSm+barkSpm*(u(4)^4/(barKSpm^4+u(4)^4))-barpmrna*Vr*u(3) ...
-bardeltamrna*u(3);
% p53_p
du(4)=bark3*u(7)*(u(1)/(barKatm+u(1)))-barkdph1*u(5)*(u(4)/(barKdph1+u(4)));
%Wip1
du(5)=barpw*Vr*u(11)-bardeltaw*u(5);
%Wip1 mRNA
du(6)=barkSw+barkSpw*(u(4)^4/(barKSpw^4+u(4)^4))-barpwrna*Vr*u(6) ...
-bardeltawrna*u(6);
% Atm_p
du(7)=2*barE*( ((ATMtot-u(7))/2)/(1+((ATMtot-u(7))/2) )) ...
2*barkdph2*u(5)*(u(7)^2/(barKdph2+u(7)^2));
% equations for the cytoplasm (B.2)
% p53
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du(8)=barkS-bark1*u(9)*(u(8)/(barK1+u(8)))-bardeltap*u(8)-barpp*(u(8)-u(1));
% Mdm2
du(9)=barktm*u(10)-barpm*(u(9)-u(2))-bardeltam*u(9);
% Mdm2 mRNA
du(10)=barpmrna*u(3)-barktm*u(10)-bardeltamrna*u(10);
% Wip1
du(11)=barktw*u(12)-barpw*u(11)-bardeltaw*u(11);
% Wip1 mRNA
du(12)=barpwrna*u(6)-barktw*u(12)-bardeltawrna*u(12);
end
40
Appendix E. Other figures and plots
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Figure E.1: Phase planes relative to the involved nuclear proteins within [E] =
0.1µM (a) Wip1 and AT Mp (b) Wip1 and p53p.
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Figure E.2: (a) The periods of the fifteen p53p pulses produced by the ODE model
within [E] = 0.1µM. The length of the first pulse is 5.16 hours, the p53p stable
limit cycle is of the period ∼6 hours.
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Figure E.3: (a) Inhibition of the negative feedback Wip1 a AT M, kdph2 = 0 in (4).
(b) Inhibition of the positive feedback AT M → p53, k3 = 0 in (6) (c) Inhibition of
the negative feedback Wip1 a p53p, kdph1 = 0 in (6). (d) Inhibition of the positive
feedback p53p → Wip1, kS pw = 0 and kS w = 0 (the basal production rate). (e)
Inhibition of the positive feedback p53p → Wip1, kS pw = 0 and kS w = 0.03 (the
basal production rate). (f) Inhibition of the positive feedback p53p → Mdm2,
kS pm = 0 and kS m = 0.005 (the basal production rate).42
References
[1] M. Kracikova, et al., A threshold mechanism mediates p53 cell fate decision
between growth arrest and apoptosis, Cell Death & Differentiation 20 (2013)
576–588.
[2] J. Clairambault, Modelling physiological and pharmacological control on cell
proliferation to optimise cancer treatments, Mathematical Modelling of Nat-
ural Phenomena 4 (2009) 12–67.
[3] J. Clairambault, O. Fercoq, Physiologically structured cell population dy-
namic models with applications to combined drug delivery optimisation in
oncology, in: M. Bachar, J. Batzel, M. Chaplain (Eds.), Mathematical mod-
elling of cancer growth and treatment, Springer, New York, 2013, Submitted.
[4] F. Murray-Zmijewski, E.A. Slee, X. Lu, A complex barcode underlies the
heterogeneous response of p53 to stress, Nature, Rev. Mol. Cell Biol. 9 (2008)
702–712.
[5] L. Dimitrio, Modelling nucleocytoplasmic transport with application to the
intracellular dynamics of the tumor suppressor protein p53 Ph.D. thesis, Uni-
versite´ Pierre et Marie Curie, Paris, 2012.
[6] L. Dimitrio, J. Clairambault, R. Natalini, A spatial physiological model for
p53 intracellular dynamics, Journal of Theoretical Biology 316 (2013) 9–24.
[7] B. Vogelstein, D. Lane, A.J. Levine, Surfing the p53 network, Nature 408
(2000) 307–310.
[8] T.T. Paull, J.H. Lee, The Mre11/Rad50/Nbs1 complex and its role as a DNA
double-strand break sensor for ATM, Cell Cycle 4:6 (2005) 737–740.
[9] F. Le´vi, A. Okyar, S. Dulong, P.F. Innominato, J. Clairambault, Circadian
Timing in Cancer Treatments, Annual Review of Pharmacology and Toxicol-
ogy 50 (2010) 377–421.
[10] A. Ballesta, S. Dulong, C. Abbara, B. Cohen, A. Okyar, J. Clairambault, F.
Le´vi, A Combined Experimental and Mathematical Approach for Molecular-
based Optimization of Irinotecan Circadian Delivery, PLoS Comput Biol
7(9): e1002143 (2011) doi:10.1371/journal.pcbi.1002143.
43
[11] A. Ballesta, J. Clairambault, S. Dulong, F. Le´vi, A Systems Biomedicine Ap-
proach for Chronotherapeutics Optimization: Focus on the Anticancer Drug
Irinotecan, in: A. d’Onofrio, P. Cerrai, A. Gandolfi (Eds.), New Challenges
for Cancer Systems Biomedicine, Part V, SIMAI Lecture Notes, Springer,
New York, 2012, 301–327.
[12] F. Billy, J. Clairambault, Designing proliferating cell population models with
functional targets for control by anti-cancer drugs, DCDS-B 18 (2013) 865–
889.
[13] Y. Sun, et al., Treatment-induced damage to the tumor microenviron-
ment promotes prostate cancer therapy resistance through WNT16B, Nature
Medicine 18 (2012) 1359–1368.
[14] E. Batchelor, et al., Recurrent Initiation: A mechanism for triggering p53
pulses in response to DNA damage, Molecular Cell 30 (2008) 277–289.
[15] S. Shreeram, et al., Wip1 Phosphatase Modulates ATM-Dependent Signaling
Pathways, Molecular Cell 23 (2006) 757–764.
[16] S. Shreeram, et al., Regulation of ATM/p53-dependent suppression of myc-
induced lymphomas by Wip1 phosphatase, The Journal of Experimental
Medicine 203 (2006) 2793–2799.
[17] G. Lahav, et al., Dynamics of the p53-Mdm2 feedback loop in individual
cells, Nature Genetics 36 (2004) 147–150.
[18] N. Geva-Zatorsky, et al., Oscillations and variability in the p53 system,
Molecular Systems Biology 2 (2006) 1–13.
[19] R. Lev Bar-Or, et al., Generation of Oscillation by the p53-Mdm2 feedback
loop: a theoretical and experimental study, Proc. Natl. Acad. Sci. USA 97
(2000) 11250–11255.
[20] D.R. Green, G. Kroemer, Cytoplasmic functions of the tumour suppressor
p53, Nature 458 (2009) 1127–1130.
[21] M.F. Lavin, Ataxia-telangiectasia: from a rare disorder to a paradigm for cell
signalling and cancer, Nature 9 (2008) 759–769.
44
[22] D.B. Young, et al., Identification of Domains of Ataxia-telangiectasia Mu-
tated Required for Nuclear Localization and Chromatin Association, The
Journal of Biological Chemistry 280 (2005) 27587–27594.
[23] M. Fiscella, et al., Wip1, a novel human protein phosphatase that is induced
in response to ionizing radiation in a p53-dependent manner, Proc. Natl. Acad.
Sci. USA 94 (1997) 6048–6053.
[24] J.Ch. Bakkenist, M.B. Kastan, DNA damage activates ATM through inter-
molecular autophosphorylation and dimer dissociation, Nature 421 (2003)
499–506.
[25] M.B. Kastan, J. Bartek, Cell-cycle checkpoints and cancer, Nature 432
(2004) 316–323.
[26] J. Bartkova, et al., ATM activation in normal human tissues and testicular
cancer, Cell Cycle 4 (2005) 838–845.
[27] R. Kitagawa, J.Ch. Bakkenist, P.J. McKinnon, M.B. Kastan, Phosphory-
lation of SMC1 is a critical downstream event in the ATM–NBS1–BRCA1
pathway, Genes & Development 18 (2004) 1423–1438.
[28] J. Falck, J. Coates, S.P. Jackson, Conserved modes of recruitment of ATM,
ATR and DNA-PKcs to sites of DNA damage, Nature 434 (2005) 605–6011.
[29] S.V. Kozlov, et al., Involvement of novel autophosphorylation sites in ATM
activation, The EMBO Journal 25 (2006) 3504–3514.
[30] S.V. Kozlov, et al., Autophosphorylation and ATM Activation: additional
sites add to the complexity, Journal of Biological Chemistry 286 (2011) 9107–
9119.
[31] Y. Sun, et al., DNA Damage-Induced Acetylation of Lysine 3016 of ATM
Activates ATM Kinase Activity, Molecular and Cellular Biology 27 (2007)
8502–8509.
[32] E. Berkovich, R.J. Monnat Jr., M.B. Kastan, Roles of ATM and NBS1 in
chromatin structure modulation and DNA double-strand break repair, Nature
Cell Biology 9 (2007) 683–690.
[33] A. Ali, et al., Requirement of protein phosphatase 5 in DNA-damage-
induced ATM activation, Genes and Development 18 (2004) 249–254.
45
[34] A.A. Goodarzi, et al., Autophosphorylation of ataxia-telangiectasia mutated
is regulated by protein phosphatase 2A, The EMBO Journal 23 (2004) 4451–
4461.
[35] J.P. Keener, J. Sneyd, Mathematical Physiology I: Cellular Physiology, sec-
ond ed., Springer, 2009.
[36] L.A. Segel, M. Slemrod, The Quasi-Steady-State Assumption: a case study
in perturbation, SIAM Review 31:3 (1989) 446–477.
[37] Y. Haupt, R. Maya, A. Kazaz, M. Oren, Mdm2 promotes the rapid degrada-
tion of p53, Nature 387 (1997) 296–299.
[38] N.D. Marchenko, et al., Stress-mediated nuclear stabilization of p53 is reg-
ulated by ubiquitination and importin-α3 binding, Cell Death and Differenti-
ation 17 (2010) 255–267.
[39] R.L. Weinberg, D.B. Veprintsev, A.R. Fersht, Cooperative binding of
tetrameric p53 to DNA, J. Mol. Biol 341 (2004) 1145–1159.
[40] L. Ma, et al., A plausible model for the digital response of p53 to DNA
damage, Proc. Natl. Acad. Sci. USA 102 (2005) 14266–14271.
[41] J. Wagner, et al., p53–Mdm2 loop controlled by a balance of its feedback
strength and effective dampening using ATM and delayed feedback, Proc.
Natl. Acad. Sci. USA 102 (2005) 109–118.
[42] A. Ciliberto, B. Novak, J.J. Tyson, Steady states and oscillations in the
p53/Mdm2 network, Cell Cycle 4 (2005) 488–493.
[43] T. Zhang, P. Brazhnik, J.J. Tyson, Exploring mechanisms of the DNA-
damage response: p53 pulses and their possible relevance to apoptosis, Cell
Cycle 6 (2007) 85–94.
[44] X.-P. Zhang, F. Liu, W. Wang, Two-phase dynamics of p53 in the DNA
damage response, Proc. Natl. Acad. Sci. USA 22 (2011) 8990–8995.
[45] J.K. Kim, T.L. Jackson, Mechanisms That Enhance Sustainability of p53
Pulses, PLoS 8(6) (2013) e65242. doi:10.1371/journal.pone.0065242.
[46] K. Puszyn´ski, B. Hat, T. Lipniacki, Oscillations and bistability in the
stochastic model of p53 regulation, J. Theor. Biol. 254 (2008) 452–465.
46
[47] M. Sturrock, A.J. Terry, D.P. Xirodimas, A.M. Thompson, M.A.J. Chap-
lain, Spatio-temporal modelling of the Hes1 and p53-Mdm2 intracellular sig-
nalling pathways, Journal of Theoretical Biology 273 (2011) 15–31.
[48] M. Sturrock, A.J. Terry, D.P. Xirodimas, A.M. Thompson, M.A.J. Chaplain,
Influence of the Nuclear Membrane, Active Transport, and Cell Shape on
the Hes1 and p53Mdm2 Pathways: Insights from Spatio-temporal Modelling,
Bulletin of Mathematical Biology 74 (2012) 1531–1579.
[49] M. Sturrock, A. Hellander, A. Matzavoinos, M.A.J. Chaplain, Spatial
stochastic modelling of the Hes1 gene regulatory network: intrinsic noise
can explain heterogeneity in embryonic stem cell differentiation, J. R. Soc.
Interface 10, 20120988 (2013) 9 pages.
[50] A. Dhooge, W. Govaerts, Y.A. Kuznetsov, Matcont: A matlab package for
numerical bifurcation analysis of ODEs, ACM TOMS 29 (2003) 141–164.
[51] Y.A. Kuznetsov, Elements of Applied Bifurcation Theory, third ed.,
Springer-Verlag, 2004.
[52] L. Dimitrio, J. Clairambault, J.P. Franc¸oise, Bifurcation in the p53 system: a
compartmental approach (2013), in preparation.
[53] Y. Lee, M.J. Chong, P.J. McKinnon, Ataxia Telangiectasia Mutated-
dependent apoptosis after genotoxic stress in the developing nervous system is
determined by cellular differentiation status, The J. of Neuroscience 21 (2001)
6687–6693.
[54] J.Ch. Bakkenist, M.B. Kastan, Initiating Cellular Stress Responses, Cell 118
(2004) 9–17.
[55] J.H. Lee, T.T. Paull, ATM activation by DNA double-strand breaks through
the Mre11-Rad50-Nbs1 complex, Science 308 (2005) 551–554.
[56] M. Sturrock, A. Hellander, S. Aldakheel, L. Petzold, M.A.J. Chaplain, The
role of dimerisation and nuclear transport in the Hes1 gene regulatory network
Bull. Math. Biol. DOI 10.1007/s11538-013-9842-5 (2013), Accepted.
47
